Official websites use .gov
Secure .gov websites use HTTPS
Tezepelumab for severe asthma: final report
Tezepelumab for severe asthma: final report
- Collection:
- Health Policy and Services Research
- Author(s):
- Rind, David M., author
Campbell, Jonathan D., author
Herce-Hagiwara, Belén, author
Herron-Smith, Serina, author
Fluetsch, Noemi, author
Pearson, Steven D., author
McQueen, R. Brett, author
Gutierrez, Eric, (Of University of Colorado), author - Contributor(s):
- Institute for Clinical and Economic Review, issuing body.
Midwest Comparative Effectiveness Public Advisory Council, issuing body. - Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, February 13, 2023
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Antibodies, Monoclonal, Humanized -- therapeutic use
Asthma -- drug therapy
United States - Genre(s):
- Technical Report
- Abstract:
- In the overall population of adults and adolescents with severe, uncontrolled asthma, tezepelumab added to standard-of-care therapy without biologics (as estimated by the placebo arm of the clinical trials) substantially reduces annualized asthma exacerbation rate (AAER). This is the case even in patients without eosinophilic asthma. However, in both eosinophilic and non-eosinophilic asthma patients the average effects of tezepelumab on daily symptoms and quality of life are small and generally smaller than the minimal clinically important difference (MCID) on scales measuring such outcomes. Improvements in AAER without large improvements in daily symptoms have been seen with other biologic therapies as well. Tezepelumab has a new mechanism of action, targeting thymic stromal lymphopoietin (TSLP). We do not find important safety signals in the clinical trials, but as noted above, new biologic therapies are frequently found to have safety concerns even after drug approval. This uncertainty is balanced by the severity of disease in the patients for whom tezepelumab is intended such that we think net harm is unlikely. Additionally, in the absence of longer-term trials, it is uncertain whether benefits may increase or decrease over time.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (various pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918697385006676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918697385006676